Elefante Mark B Acquires 463 Shares of Danaher Corporation $DHR

Elefante Mark B grew its position in Danaher Corporation (NYSE:DHR) by 2.5% in the second quarter, according to its most recent filing with the SEC. The fund owned 19,112 shares of the conglomerate’s stock after acquiring an additional 463 shares during the period. Danaher accounts for approximately 2.8% of Elefante Mark B’s investment portfolio, making the stock its 16th biggest position. Elefante Mark B’s holdings in Danaher were worth $3,775,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Danaher by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock valued at $12,296,123,000 after acquiring an additional 230,966 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Danaher by 3.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after acquiring an additional 612,154 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Danaher by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate’s stock valued at $1,800,614,000 after acquiring an additional 194,466 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after acquiring an additional 1,450,703 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Danaher by 4.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate’s stock valued at $867,168,000 after purchasing an additional 163,332 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a report on Friday, June 27th. Bank of America decreased their price objective on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a report on Monday, September 22nd. Barclays restated an “overweight” rating and issued a $225.00 price objective (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. UBS Group decreased their price objective on Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, July 23rd. Finally, Rothschild Redb downgraded Danaher from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 8th. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $244.60.

Danaher Stock Performance

Shares of Danaher stock opened at $205.36 on Tuesday. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The business has a 50-day moving average price of $200.82 and a two-hundred day moving average price of $197.06. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.41. The company has a market cap of $147.05 billion, a P/E ratio of 43.69, a PEG ratio of 2.88 and a beta of 0.77.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same period last year, the business posted $1.72 EPS. The business’s revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher’s dividend payout ratio (DPR) is presently 27.23%.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director owned 20,751 shares of the company’s stock, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 11.20% of the stock is owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.